Infinity Pharmaceuticals, Inc.

Quick facts

Marketed products

• Placebo plus Docetaxel · Oncology
  Docetaxel is a microtubule-stabilizing chemotherapy agent that disrupts cell division, combined with placebo as a control comparator.

Phase 2 pipeline

• IPI 504 plus Docetaxel
• IPI-926

Phase 1 pipeline

• IPI-504, docetaxel
• IPI-926 plus gemcitabine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Infinity Pharmaceuticals, Inc. portfolio CI brief
• Infinity Pharmaceuticals, Inc. pipeline updates RSS